Alphamab Oncology Receives Approval for JSKN033 Clinical Trial

Alphamab Oncology (HK:9966) has released an update.

Alphamab Oncology has announced the approval of a phase I/II clinical trial for their innovative drug JSKN033, a subcutaneous co-formulation targeting HER2 and PD-L1, by the Center for Drug Evaluation in China. This trial aims to test the safety and efficacy of the drug in patients with advanced metastatic tumors. The company’s advancements in biopharmaceutical technology continue to position them as leaders in oncology drug development.

For further insights into HK:9966 stock, check out TipRanks’ Stock Analysis page.